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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the impact and cost-effectiveness of different types of death review in reducing maternal, perinatal and child mortality.
B A C K G R O U N D
Description of the condition
’Maternal mortality’ is defined as the death of a woman during
pregnancy or within 42 days of delivery, from any cause related to
or aggravated by the pregnancy or its management but not from
accidental or incidental causes (WHO 2004). ’Perinatal mortality’
is defined as the stillbirth or death of a newborn baby within the
first seven days of life (WHO 2006). ’Child mortality’ is defined
as the death of a child under the age of five years (UNICEF
2015). The maternal mortality ratio and child mortality rate are
expressed per 100,000 live births (UNICEF 2015; WHO 2014).
The perinatal mortality rate is expressed per 1000 total births
(WHO 2006).
The United Nations’ Sustainable Development Goals include re-
ducing the global maternal mortality ratio to less than 70 per
100,000 live births and ending preventable deaths of newborns
and children under five years of age, with all countries aiming
to reduce neonatal mortality to at least as low as 12 per 1000
live births and mortality in children aged less than five years to
at least as low as 25 per 1000 live births, by 2030 (UN 2017).
Although progress is being made towards achieving these goals,
it is not fast enough, especially in low-income countries (Wang
2014; WHO 2014). The absolute number of maternal, child and
perinatal deaths, and the corresponding death rates, are higher in
Africa than in any other region. In 2015, there were an estimated
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303,000 maternal deaths globally, 99% of which were in low- and
middle-income countries, and 66% in sub-Saharan Africa alone
(WHO 2015). In 2016, there were an estimated 5,642,000 child
deaths globally, more than half of which occurred in sub-Saharan
Africa (UNICEF 2017).
Description of the intervention
’Death audit and review’ is a broad term intended to include ev-
ery different method of reviewing deaths, which we define as not
only identifying the medical cause of death, but also identifying
avoidable factors and making recommendations for avoiding such
deaths in the future. The principle methods used are community-
based audit (verbal and social autopsy), facility-based audits (sig-
nificant event analysis (SEA)) and a combination of both (confi-
dential enquiry).
In low-income countries without comprehensive death registra-
tion, deaths in the community are often investigated using verbal
autopsy. The family of the deceased is interviewed according to a
standard questionnaire (developed by WHO 2007), and the in-
formation is then interpreted by physicians or by a computer to
ascertain the most likely medical cause of death (Waiswa 2010).
However, there is usually no attempt to identify avoidable factors
as it is assumed that it is already known which interventions are
needed to tackle each principle disease. Verbal autopsy has been in-
corporated into wider health and demographic surveillance strate-
gies (Adazu 2005), although its accuracy has been questioned due
to the non-specific nature of signs and symptoms that may not be
easily observed or remembered at interview (Butler 2010; Sloan
2001; Waiswa 2010). Social autopsy was designed as an add-on
to verbal autopsy, and indeed the two are sometimes combined
as a ’verbal and social autopsy’ (VASA) (Kalter 2011). The aim is
to make a ’social diagnosis’, identifying avoidable factors prior to
death in the home and community, within health facilities and at
different stages of the patient pathway. In India this has been used
in a participatory manner, which has been termed social audit for
community action (SACA) (Nandan 2005). In this method, the
community is asked to identify causes of death and avoidable fac-
tors. In this review we will not include studies investigating stand-
alone verbal autopsy (whether conducted by a physician or a com-
puter) with the sole purpose of identifying the medical cause of
death.
Death audits in health facilities are usually based on SEA.This is an
important part of revalidation for doctors in theUK, and the Royal
College of General Practitioners (RCGP 2014) recommends that
“SEA team discussions should be a routine part of your practice’s
quality improvement and clinical governance”. Cases are usually
discussed in a multidisciplinary teammeeting (Hussein 2007). Af-
ter discussing the details of the case, health workers identify avoid-
able factors and learning needs, and propose actions to be taken
and changes to be made. The process does not intend to place
blame, but the names of staff involved are not kept confidential.
Indeed it is argued that “non-confidential straightforwardness and
open-mindedness” are vital for a successful strategy (Supratikto
2002). A similar process occurs in ’mortality meetings’, ’root cause
analysis’ meetings and, indeed, ’serious case reviews’ (in child pro-
tection cases). Most mortality meetings take place at secondary
healthcare facilities, drawing upon medical records to identify the
diagnosis and keymanagement interventions. Severe morbidity or
near-miss reviews are also used to learn lessons; these review cases
in which an individual almost died.
Confidential enquiry is themost comprehensive method by which
to investigate deaths, because it considers not only the diagnosis
and treatment in health facilities, but also the entire course of an ill-
ness and treatment-seeking pathway, to identify avoidable factors
and to recommend changes at every level of the health and social
care system and beyond, in order to prevent future deaths. This
is particularly important in low-income countries where the ma-
jority of child deaths occur outside of any health facility (Breman
2001). A key feature of such enquiries is that the names of the in-
dividuals and any health workers involved are kept confidential, so
that blame is avoided. These enquiries were pioneered in high-in-
come countries, based entirely onwritten (usuallymedical) records
examined by a multidisciplinary panel of experts, which includes
not only health workers but also other professionals such as social
services and the police (Lewis 2011; Pearson 2008). Such confi-
dential enquiries have been useful for evaluating gaps in healthcare
in the UK (Pearson 2008; WHO 2004), but are not yet widely
used in low-income countries (Hussein 2007). The expert analysis
involves both quantitative and qualitative elements. In the UK, all
the included deaths were analysed quantitatively for basic infor-
mation such as age, sex, socioeconomic status, location of death,
time (seasonality) of death, and cause of death. Further detailed
investigations were carried out on all maternal deaths and a subset
of child deaths. A multidisciplinary panel reviewed each of these
cases and identified avoidable factors. These were analysed the-
matically, illustrated by cases, and were used to generate recom-
mendations as to how deaths might be avoided in future (Pearson
2008a).
How the intervention might work
Participation by communities in death audits is a strong basis for
collective action to reducemortality. In health facilities, significant
event audit is a potentially powerful intervention to enable staff
to learn from their mistakes and to institute important changes to
procedures within their institution; the key mechanism is believed
to be recommendation, then implementation of the proposed so-
lutions (Pattinson 2009). The confidential enquiry approach is
designed to identify avoidable factors at every step of the treat-
ment-seeking pathway, and to make recommendations not only
to improve the health system, but also to address avoidable fac-
tors outside of health facilities. Case review meetings, followed by
the dissemination of recommendations to health workers, com-
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munities, or both, are essentially aiming to change clinician and
patient behaviour. There are many theories of behaviour change,
but these have been synthesised and integrated into the theoretical
domains framework, which consists of 14 domains (Cane 2012;
Michie 2014).Many of these domains are addressed by death audit
and review. Those participating in the death review meetings gain
knowledge about avoidable factors. The recommendations often
set goals, and progress towards these can be audited. Repetition of
similar recommendations may help clinicians to better remember
guidelines, whereas social pressure may encourage them to better
follow these guidelines. Death review meetings may also change
health workers’ beliefs about the consequences of their actions: the
knowledge that deaths will be investigated and reviewed may mo-
tivate them to avoid poor practice. Discussing deaths, especially of
mothers and children, often evokes an emotional response, which
usually motivates health workers and parents to do all they can to
prevent such deaths.
Death reviews may conceivably have some adverse effects. First,
there is a cost (time and financial) to conducting death reviews. In
the community, field workers need to be employed to investigate
cases. In health facilities, staff are taken away from frontline duties
to review cases, which may have an adverse impact on the delivery
of care. It has been argued that these resources should instead be
spent directly on implementing interventions that are known to
be effective (Koblinsky 2017). Second, if death reviews are not
handled sensitively, they may lead to blaming, humiliation and
demotivation of staff, which may in turn lead to poorer quality
of care. Third, focus on only one level of care (such as a district
hospital) may lead to the diversion of resources away from other
levels of care (such as primary care facilities). Fourth, there is the
potential for inaccuracy - reviews based on indirect information
(especially at the community level) may be incomplete or inade-
quate at diagnosing the likely cause of death.
Why it is important to do this review
The World Health Organization recommends that health facili-
ties should conduct maternal and perinatal death reviews (WHO
2013;WHO 2016). In general, there is an underlying assumption
that death reviews are useful andwill impact onmortality but there
is little robust evidence to support this (Pattinson 2005). It would
be useful for policy-makers to understand which type of death
review has the greatest impact on maternal, perinatal and child
death rates, and what the essential features of an effective death
review process are. Although confidential enquiry seems to be the
most comprehensive method for addressing the whole range of
avoidable factors, and hence has the potential to have the greatest
impact, it is unclear whether it could be adapted, whether it would
be feasible or whether it would be effective in reducing mortality
in low-income countries.There is no comprehensive systematic re-
view in the literature examining the impact of the aforementioned
methods of investigating deaths.
O B J E C T I V E S
To assess the impact and cost-effectiveness of different types of
death review in reducing maternal, perinatal and child mortality.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewill include cluster randomised trials. However, as these are ex-
pensive and difficult to conduct, and large sample sizes are needed
to measure impact on mortality, we therefore anticipate that we
will find very few. We therefore will also include cluster non-ran-
domised trials, studies with a step-wedge design, controlled be-
fore-and-after studies and interrupted time series studies.
For cluster randomised trials, cluster non-randomised trials and
controlled before-and-after studies, we will use the Effective Prac-
tice and Organisation of Care (EPOC) criteria (EPOC 2017a)
and will exclude studies with only one intervention or control site;
for interrupted time series studies, we will exclude studies that do
not have a clearly defined point in time when the intervention
occurred and at least three data points before and three after the
intervention.
Types of participants
Participants receiving the intervention (audits and reviews of
deaths) can be health facilities of any level or the wider community,
such as subdistricts or districts in which the policy is implemented,
or both. Participants who should benefit from the intervention are
pregnant women giving birth and their children at the study sites
during the study period in which the outcomes are measured.
Types of interventions
We will include any form of death audit or review that involves
studying individual cases of deaths, identifying avoidable factors,
and making recommendations. We will classify the interventions
as verbal and social autopsy, facility-based death audit and SEA,
or confidential enquiry. We will not include verbal autopsy stud-
ies that evaluated only causes of death, and not avoidable factors.
We will include studies of maternal, perinatal, newborn and child
deaths, alone or in combination. We will not include severe mor-
bidity or near-miss reviews. We will include comparisons of the
same population before introduction of the death review, or other
comparable communities in which the death review was not im-
plemented.
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Types of outcome measures
We plan to include studies in the review irrespective of whether
measured outcome data are reported in a ‘usable’ way. We will
include and describe in a ’Characteristics of included studies’ table
studies that meet the inclusion criteria.
Main outcomes
To be included in the review, a study will need to report at least
one of the following outcomes:
• perinatal mortality rate;
• stillbirth rate;
• neonatal mortality rate;
• mortality rate in children under five years of age;
• maternal mortality ratio.
Secondary outcomes
For included studies, we will also consider other outcomes:
• outcomes relating to maternal severe morbidity, such as
maternal near miss or as defined by authors;
• outcomes relating to quality of care in participating
facilities;
• cost per death averted.
Search methods for identification of studies
Electronic searches
We will search the following databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library;
• MEDLINE Ovid;
• Embase Ovid,
• Global Health Ovid;
• Global Health Library - Regional Indexes;
• Popline;
• CINAHL EBSCO Host (Cumulative Index to Nursing and
Allied Health Literature Host);
• Science Citation Index, Web of Science Core Collection;
• Conference Proceedings Citation Index - Science, Web of
Science Core Collection.
We provide aMEDLINE search strategy, with no language or pub-
lication date limits, in Appendix 1. We will adapt the MEDLINE
strategy for use with all the other databases.
Searching other resources
We will identify ongoing studies through searches of ClinicalTri-
als.gov and the WHO International Clinical Trials Registry Plat-
form (http://www.who.int/ictrp/en/). We will search Google and
the websites of the World Bank and the WHO. We will identify
relevant articles from the reference lists of articles found in these
searches. We will contact experts in the field to advise us of un-
published or grey literature, and we will also search the two grey
literature collections, OpenGrey and the Grey Literature Report.
Data collection and analysis
Selection of studies
We will download all titles and abstracts retrieved by electronic
searching to a reference management database and remove dupli-
cates. Two review authors will independently screen titles and ab-
stracts for inclusion. We will retrieve the full-text study reports/
publications and two review authors will independently screen the
full text, identify studies for inclusion, and identify and record
the reasons for exclusion of ineligible studies. We will resolve any
disagreement through discussion or, if required, we will consult a
third reviewer. We will list studies that initially appeared to meet
the inclusion criteria but were later excluded, together with reasons
for exclusion, in a ’Characteristics of excluded studies’ table. We
will collate multiple reports of the same study so that each study
rather than each report is the unit of interest in the review. We
will also provide any information we can obtain about ongoing
studies. We will record the selection process in sufficient detail to
complete a PRISMA flow diagram (Liberati 2009) and a ’Charac-
teristics of excluded studies’ table.
Data extraction and management
We will use a standard data collection form, adapted from the
Cochrane good practice data collection form, for study character-
istics and outcome data.Wewill first pilot this on at least one study
in the review. Two review authors (MW, JP) will independently
extract the following study characteristics from included studies.
1. Methods: study design, number of study centres and
location, study setting, withdrawals, date of study, follow-up.
2. Participating health facilities: number, inclusion criteria,
exclusion criteria, other relevant characteristics.
3. Interventions: intervention components, comparison,
fidelity assessment.
4. Outcomes: main and other outcomes specified and
collected, time points reported.
5. Notes: funding for trial, notable conflicts of interest of trial
authors, ethical approval.
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Two review authors (MW and JP) will independently extract out-
come data from included studies. We will note in the ’Characteris-
tics of included studies’ table whether outcome data were reported
in an unusable way. We will resolve disagreements by consensus
or by involving a third review author (AH or AD).
Assessment of risk of bias in included studies
Two review authors (MWand JP)will independently assess the risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011)
and the guidance from the EPOC group (EPOC 2017b). We will
resolve any disagreement by discussion or by involving a third
review author (AHor AD).Wewill assess the risk of bias according
to the following domains.
Cluster randomised trial/cluster non-randomised trial/controlled
before-and-after study criteria:
• random sequence generation;
• allocation concealment;
• blinding of participants and personnel;
• blinding of outcome assessment;
• incomplete outcome data;
• selective outcome reporting;
• baseline outcomes measurement;
• baseline characteristics;
• other bias.
Interrupted time series study criteria:
• was the intervention independent of other changes?
• was the shape of the intervention effect prespecified?
• was the intervention unlikely to affect data collection?
• was knowledge of the allocated interventions adequately
prevented during the study?
• were incomplete outcome data adequately addressed?
• was the study free from selective outcome reporting?
• was the study free from other risks of bias?
We will judge each potential source of bias as high, low or unclear,
and provide a quote from the study report together with a justifi-
cation for our judgement in the ’Risk of bias’ table. We will sum-
marise our ’Risk of bias’ judgements across different studies for
each of the domains listed. We will consider blinding separately
for different key outcomes where necessary (e.g. for unblinded
outcome assessments, risk of bias for all-cause mortality may be
very different than for a participant-reported pain scale). Where
information on risk of bias relates to unpublished data or corre-
spondence with a trialist, we will note this in the ’Risk of bias’
table. We will not exclude studies on the grounds of their risk of
bias, but will clearly report the risk of bias when presenting the
results of the studies.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assesment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations from it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Measures of treatment effect
We will estimate the effect of the intervention using risk ratios for
dichotomous data, together with the appropriate associated 95%
confidence intervals, and mean differences or standardised mean
differences for continuous data, togetherwith the 95%appropriate
associated confidence intervals. We will ensure that an increase in
scores for continuous outcomes can be interpreted in the same
way for each outcome, explain the direction to the reader and
report where the directions were reversed if this was necessary.
For interrupted time series studies, we will estimate a standardised
effect size for each study by dividing the level by the slope and the
standard error by the standard deviation of the preintervention
slope. We will enter the effect sizes for level and slope in Review
Manager 5 (Cochrane 2014) using the generic inverse variance
method (Ramsay 2003).
Unit of analysis issues
For cluster randomised trials, we plan to conduct the analysis at the
same level as the allocation using a summary measure from each
cluster. However, if this appears to unnecessarily reduce the power
of the study due to the number and size of the clusters, we will seek
statistical advice to determine if a risk ratio or standardised mean
difference with confidence intervals can be calculated to account
for the cluster design based on a ’multilevel model’ or another
appropriate method.
Dealing with missing data
If important data are missing, we will contact authors to attempt
to obtain the data. We will use intention-to-treat analyses by in-
cluding all participants that were supposed to have received a par-
ticular intervention. If necessary, we will also perform sensitivity
analyses by excluding studies with high rates of loss to follow-up.
Assessment of heterogeneity
We plan to assess statistical heterogeneity in each meta-analysis vi-
sually and using the I² and Chi² statistics, regarding heterogeneity
as substantial if the I² statistic is greater than 60% or if there is a
low P value (less than 0.10) in the Chi² test for heterogeneity.
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Assessment of reporting biases
If there are 10 or more studies in themeta-analysis, we will investi-
gate reporting biases (such as publication bias) using funnel plots.
We will assess funnel plot asymmetry visually, and we will conduct
formal tests for funnel plot asymmetry, using the metabias com-
mand in STATA. We will use the test proposed by Egger 1997,
which can be implemented easily in STATA.
Data synthesis
We will undertake meta-analyses only where they are meaning-
ful (i.e. if the treatments, participants and the underlying clinical
question are similar enough for pooling to make sense). A com-
mon way that trialists indicate when they have skewed data is by
reporting medians and interquartile ranges. When we encounter
this we will note that the data are skewed and consider the implica-
tion of this.Wheremultiple trial arms are reported in a single trial,
we will include only the relevant arms. If two comparisons (e.g.
intervention A versus usual care and intervention B versus usual
care) must be entered into the same meta-analysis, we will halve
the control group to avoid double counting. If studies are homo-
geneous enough for pooling their results to be clinically meaning-
ful, we will perform ameta-analysis using a random-effects model.
We will perform the analysis using RevMan (Cochrane 2014) and
produce forest plots for all analyses.
We will extract data in the included studies on costs per death
averted as reported by the study authors, but we will not attempt
to calculate these costs.
Summary of findings
We will summarise the findings of the main intervention compar-
ison for the most important outcomes:
• perinatal mortality rate;
• stillbirth rate;
• neonatal mortality rate;
• mortality rate in children under five years of age;
• maternal mortality ratio.
We will present these in a ’Summary of findings’ table to draw
conclusions about the certainty of the evidence within the text
of the review. Two review authors will independently assess the
certainty of the evidence (high, moderate, low or very low) us-
ing the five GRADE considerations (study limitations, consis-
tency of effect, imprecision, indirectness and publication bias). We
will use the methods and recommendations described in Section
8.5 and Chapter 12 of the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011) and the EPOC worksheets
(EPOC 2017c), and using GRADEpro software (GRADEpro
GDT 2015).We will resolve disagreements on certainty ratings by
discussion, provide justification for decisions to down- or upgrade
the ratings using footnotes in the table and make comments to aid
readers’ understanding of the review where necessary. We will use
plain language statements to report these findings in the review.
We will consider whether there is any additional outcome infor-
mation that was not able to be incorporated into meta-analyses,
note this in the comments and state if it supports or contradicts
the information from the meta-analyses. If it is not possible to
meta-analyse the data we will summarise the results in the text.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses:
1. type of country (low- versus middle- versus high-income,
according to World Bank classification at the time of the study);
2. type of death review (verbal and social autopsy versus SEA
versus confidential enquiry);
3. setting: facility-based versus community-based.
The following outcomes will be used in subgroup analysis:
1. perinatal mortality rate;
2. stillbirth rate;
3. neonatal mortality rate;
4. mortality rate in children under five years of age;
5. maternal mortality ratio.
Sensitivity analysis
We will perform sensitivity analysis defined a priori to assess the
robustness of our conclusions and explore its impact on effect sizes.
This will involve:
1. restricting the analysis to published studies;
2. restricting the analysis to studies with a low risk of bias (i.e.
high-quality randomised trials).
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
MEDLINE, Ovid
# Searches Results
1 (child mortality/ or fetal mortality/ or infant mortality/ or ma-
ternal mortality/ or perinatal mortality/) and (clinical audit/
or medical audit/)
348
2 (Pregnant Women/ or exp Child/) and (“cause of death”/ or
Mortality/) and (clinical audit/ or medical audit/)
57
3 (Pregnancy Complications/mo or Stillbirth/ or Suddent Infant
Death/) and (clinical audit/ or medical audit/)
85
4 ((maternal or mother* or maternity or child* or infan* or p?
ediatric* or fetal or foetal or perinatal or pregnan* or childbirth
or birth or labo?r) adj3 (mortality or death?)).ti,ab. and (clinical
audit/ or medical audit/)
438
5 (stillbirth? or sudden infant death? or sids or cot death? or crib
death?).ti,ab. and (clinical audit/ or medical audit/)
62
6 (child mortality/ or fetal mortality/ or infant mortality/ or ma-
ternal mortality/ or perinatal mortality/) and (review* or au-
dit* or meeting? or enquir* or inquir*).ti,ab
4594
7 (Pregnant Women/ or exp Child/) and (“cause of death”/ or
Mortality/) and (review* or audit* or meeting? or enquir* or
inquir*).ti,ab
1732
8 (Pregnancy Complications/mo or Stillbirth/ or Suddent Infant
Death/) and (review* or audit* or meeting? or enquir* or in-
quir*).ti,ab
1034
9 (((death? or mortality) adj3 (review* or audit* or meeting? or
enquir* or inquir*)) and (maternal or mother* or maternity or
child* or infan* or p?ediatric* or fetal or foetal or perinatal or
pregnan* or childbirth or birth or labo?r)).ti,ab
2169
10 ((stillbirth? or sudden infant death? or sids or cot death? or
crib death?) adj5 (review* or audit* or meeting? or enquir* or
inquir*)).ti,ab
346
11 ((confidential enquir* or confidential inquir*) and ((maternal
or mother* or maternity or child* or infan* or p?ediatric* or
341
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(Continued)
fetal or foetal or perinatal or pregnan* or childbirth or birth or
labo?r) adj3 (mortality or death?))).ti,ab
12 ((confidential enquir* or confidential inquir*) and (stillbirth?
or sudden infant death? or sids or cot death? or crib death?)).
ti,ab
61
13 (cemach or cmace or cemd or cmde).ti,ab. 66
14 (saving mothers lives or making pregnancy safer or making
childbirth safer).ti,ab
45
15 ((verbal autops* or social autops*) adj5 (maternal or mother*
or maternity or child* or infan* or p?ediatric* or fetal or foetal
or perinatal or pregnan* or childbirth or birth or labo?r)).ti,ab
118
16 ((near miss* or significant event* or critical event* or critical
incident?) and (maternal or mother* or maternity or child* or
infan* or p?ediatric* or fetal or foetal or perinatal or pregnan* or
childbirth or birth or labo?r) and (review* or audit* ormeeting?
or enquir* or inquir*)).ti,ab
374
17 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or
13 or 14 or 15 or 16
8610
18 exp Animals/ not humans/ 4743197
19 17 not 18 8579
20 randomized controlled trial.pt. 505457
21 controlled clinical trial.pt. 100426
22 multicenter study.pt. 254745
23 pragmatic clinical trial.pt. 762
24 non-randomized controlled trials as topic/ 266
25 interrupted time series analysis/ 387
26 controlled before-after studies/ 313
27 (randomis* or randomiz* or randomly).ti,ab. 820831
28 groups.ab. 1884241
10Death audits and reviews for reducing maternal, perinatal and child mortality (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
29 (trial or multicenter or multi center or multicentre or multi
centre).ti
234468
30 (intervention? or effect? or impact? or controlled or control
group? or (before adj5 after) or (pre adj5 post) or ((pretest or pre
test) and (posttest or post test)) or quasiexperiment* or quasi
experiment* or pseudo experiment* or pseudoexperiment* or
evaluat* or time series or time point? or time trend? or repeated
measur* or step* wedg*).ti,ab
8860150
31 exp “Costs and Cost Analysis”/ 224968
32 economics/ or exp economics, hospital/ or exp economics,
medical/
64522
33 “Value of Life”/ 5842
34 quality-adjusted life years/ 10860
35 Decision Trees/ 10839
36 economic evaluation*.ti,ab. 10364
37 (Cost* adj2 (Effective* or analysis* or Utility* or Benefit* or
Minimi*)).ti,ab
145738
38 (pharmacoeconomic* or pharmaco-economic*).ti,ab. 4036
39 economic*.ti. 42813
40 (“Value of life” or “quality adjusted life year*” or qaly* or qald*
or qale* or “disability adjusted life year*” or daly).ti,ab
15327
41 (sf6 or short form 6 or shortform6 or euroqol or euro quality
of life or eq5d or eq-5d).ti,ab
9979
42 (hye or health* year equivalent*).ti,ab. 62
43 (health utilit* or disutilit*).ti,ab. 2170
44 “willingness to pay”.ti,ab. 4341
45 standard gamble.ti,ab. 867
46 (time trade off or time tradeoff or tto).ti,ab. 1748
47 (vas or visual analog*).ti,ab. 69360
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(Continued)
48 ((economic adj2 model*) or markov or monte carlo method).
ti,ab
24887
49 (decision* adj (tree* or model* or analysis)).ti,ab. 12985
50 (resource* adj (use* or utilisation)).ti,ab. 9810
51 ((healthcare or health care or direct service or hospital or drug*)
adj cost*).ti,ab
31583
52 or/20-51 10160587
53 review.pt. 2480561
54 meta analysis.pt. 94844
55 news.pt. 190065
56 comment.pt. 734842
57 editorial.pt. 470195
58 cochrane database of systematic reviews.jn. 14591
59 comment on.cm. 734840
60 (systematic review or literature review).ti. 112324
61 or/53-60 3760993
62 52 not 61 9136353
63 19 and 62 2910
C O N T R I B U T I O N S O F A U T H O R S
Conceiving the protocol: all authors
Designing the protocol: MW, BN, JP, BS, AD, AH
Coordinating the protocol: MW
Designing search strategies: MW, NR
Writing the protocol: MW, BN, JP, BS
Providing general advice on the protocol: AH, AD
Performing previous work that was the foundation of the current study: AD, MW, BN, AH, HA, VM
12Death audits and reviews for reducing maternal, perinatal and child mortality (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D E C L A R A T I O N S O F I N T E R E S T
Merlin L Willcox: no known conflicts of interest
Brian D Nicholson: no known conflicts of interest
Jessica Price: no known conflicts of interest
Beth Stuart: no known conflicts of interest
Nia Roberts: no known conflicts of interest
Helen Allott: no known conflicts of interest
Vincent Mubangizi: no known conflicts of interest
Alexandre Dumont: no known conflicts of interest
Anthony Harnden: no known conflicts of interest
13Death audits and reviews for reducing maternal, perinatal and child mortality (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
